136 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
5 Jun 24
Regulation FD Disclosure
6:04am
of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar … changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk
8-K
VIR
Vir Biotechnology Inc
5 Jun 24
Regulation FD Disclosure
6:04am
furnished herewith as Exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words … or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
and SG&A expenses; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks … of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
activities, litigation, in-process R&D impairments, and changes in the fair value of contingent considerations.
Conference Call
Vir will host a conference … .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
8-K
EX-99.1
txlt7bs2
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
8-K
EX-99.1
r2hmx08o37
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
mrc sbh6tuvaobzn
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
S-3ASR
EX-1.2
uu5mzc
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
ldu3c3 i2pl
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
keurt
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
yrc hnjpn0m4usf7
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
cqq49n gz5i
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
l5129z6
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
9sx2jsfkq sqvv
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm